Kevin Brewton, MD
Urology · Battle Creek, MINPI 1861402836
Payments from drug & device makers
Across 205 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Astellas Pharma US Inc$959
- Johnson & Johnson$491
- Pfizer$262
- Sumitomo Pharma America, Inc.$220
- AbbVie$162
- plus $2K from 32 others
What the payments were for
- Travel & lodging$1,42724%
- Food & beverage$3,69062%
- Education$84314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 12 | $1,806 |
| Astellas Pharma US Inc | 35 | $959 |
| Johnson & Johnson(2 entities) | 16 | $491 |
| Pfizer | 23 | $262 |
| Sumitomo Pharma America, Inc. | 11 | $220 |
| AbbVie(2 entities) | 11 | $162 |
| C. R. Bard, Inc. & Subsidiaries | 14 | $161 |
| Teleflex LLC | 6 | $154 |
| Endo Pharmaceuticals Inc. | 7 | $143 |
| Dendreon Pharmaceuticals LLC | 5 | $130 |
| Procept Biorobotics Corporation | 3 | $129 |
| Olympus America Inc. | 4 | $127 |
| Urogen Pharma, Inc. | 4 | $107 |
| Ferring Pharmaceuticals Inc. | 4 | $102 |
| Endo USA, Inc. | 4 | $96 |
| Coloplast | 5 | $96 |
| Tempus AI, Inc | 3 | $92 |
| Myriad Genetic Laboratories, Inc. | 5 | $85 |
| Valencia Technologies Corporation | 1 | $69 |
| Bayer | 3 | $51 |
| Blue Earth Diagnostics | 2 | $45 |
| Laborie Medical Technologies Corp. | 4 | $43 |
| Myovant Sciences Inc. | 2 | $43 |
| Progenics Pharmaceuticals, Inc. | 2 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $41 |
| Calyxo, Inc. | 1 | $40 |
| Janssen Scientific Affairs, LLC | 2 | $35 |
| Ambu Inc. | 1 | $33 |
| Koelis Inc. | 2 | $31 |
| AstraZeneca | 2 | $26 |
| Dentsply IH Inc. | 2 | $26 |
| Smith+Nephew | 1 | $24 |
| Intuitive Surgical | 1 | $18 |
| Acacia Pharma Inc | 1 | $18 |
| SRS Medical Systems, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $13 |
| Amgen | 1 | $12 |
How this compares
$5,960 in reported general payments places this provider in the 65th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 51 | $673,940 |
| ErleadaApalutamide | 13 | $197,015 |
| MyrbetriqMirabegron | 35 | $25,859 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 70 | $11,197 |
| Tolterodine Tartrate ErTolterodine Tartrate | 86 | $7,208 |
| Tamsulosin Hcl | 214 | $4,469 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 83 | $3,424 |
| Dutasteride | 67 | $2,894 |
| Finasteride | 139 | $2,698 |
| Pentoxifylline | 22 | $1,406 |
| Estradiol | 19 | $1,372 |
| Bicalutamide | 11 | $273 |
| Meloxicam | 12 | $148 |
| Ketorolac Tromethamine | 13 | $124 |
| Cephalexin | 31 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $959 | $699,80086 claims |
| Johnson & JohnsonErleada | $491 | $197,01513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 400 urology providers in Michigan.
Other urology in Battle Creek
- Richard SarleBattle Creek$33K
- Jason HafronWest Bloomfield$9.9M
- Ashok ReddySterling Heights$4.9M
- Kenneth KernenTroy$3.4M
- James PeabodyDetroit$2.1M
- William RobertsAnn Arbor$973K
- Adam GadzinskiRoyal Oak$727K
- William JohnstonLivonia$675K
- Kenneth PetersRoyal Oak$590K
- Khurshid GhaniAnn Arbor$550K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.